Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Probi AB (publ)
  6. News
  7. Summary
    PROB   SE0001280355

PROBI AB (PUBL)

(PROB)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 05/18 11:29:49 am
483.5 SEK   +1.58%
05/10PROBI AB (PUBL) : Ex-dividend day for final dividend
FA
05/07PROBIá : Annual General Meeting 2021
AQ
04/23Q1 2021 : Good growth in the first quarter
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Probi and Sinopharm enter strategic partnership in China

03/29/2021 | 04:01am EDT

The Swedish probiotic supplier, Probi® and Sinopharm, one of China's largest pharmaceutical & healthcare companies enter a partnership to expand the offering of premium probiotic offerings in the Chinese market.

Sinopharm will launch three probiotic supplements within the immune health, bone health and iron absorption areas based on Probi's scientifically proven probiotic strains.

Zhang Jian Ge, Director Pharmaceutical & Chemical Division of Sinopharm, states: "Sinopharm continues to commit to our strong sense of social responsibility of "caring for life, attending to health". Guided by our core value "All for health, health for all", Sinopharm's recent strategic partnership with Probi, especially its best-in-class R&D capability helps us contribute with positive impact to China's consumer healthcare industry."

And she continues: "The products have clinically documented positive effects and will be introduced under a new brand to expand Sinopharm's existing supplement portfolio."

Probiotics are a high-growth segment in China with a growth rate of 10.3% CAGR in the next 5 years according to Euromonitor.

Veronica Dong, Head of APAC, Probi: "We are excited to partner with Sinopharm, who shares our vision of bringing innovative and scientifically supported products into China and the APAC region. With this partnership Probi has demonstrated its position as a leading probiotic company to capture high growth markets in the region such as China."

"The partnership between Probi and Sinopharm is an important step in our commercial efforts in offering clinically documented probiotic products to consumers all over the world, and our expansion into China is a good step forward in establishing Probi's position in the APAC region. In our partnership with Sinopharm we feel commitment and alignment in offering high quality products based upon research, clinical documentation and performance," says Tom Rönnlund, CEO at Probi.

 

For further information, please contact:

Tom Rönnlund, CEO, Probi®,
Phone: +46 46 286 89 40, E-mail: trd@probi.com
Veronica Dong, Head of APAC, Probi®Phone: +65 6439 2313, E-mail: veronica.dong@probi.com
Charlotte Beyerholm, Director Marketing & Global Communication, Probi®,
Phone: +46 76 870 94 65, E-mail: charlotte.beyerholm@probi.com

 

ABOUT PROBI

Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical
documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to
more than 40 markets. We hold more than 400 patents globally. Read more at www.probi.com.

Probi® is a registered trademark of Probi AB.

ABOUT Sinopharm

China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.
Sinopharm owns over 1,100 subsidiaries and 6 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., and China Traditional Chinese Medicine Holdings Co., Ltd.

https://news.cision.com/probi/r/probi-and-sinopharm-enter-strategic-partnership-in-china,c3315059

https://mb.cision.com/Main/1556/3315059/1393446.pdf

https://news.cision.com/probi/i/gettyimages-952063610-small,c2893949

(c) 2021 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. -0.29% 40.7 End-of-day quote.-11.14%
CHINA NATIONAL MEDICINES CORPORATION LTD. -1.33% 37.07 End-of-day quote.-24.82%
CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 1.99% 4.61 End-of-day quote.20.05%
PROBI AB (PUBL) 1.58% 483.5 Delayed Quote.12.80%
SINOPHARM GROUP CO., LTD. 0.77% 26.1 End-of-day quote.38.39%
SYMRISE AG -0.38% 104.6 Delayed Quote.-3.14%
All news about PROBI AB (PUBL)
05/10PROBI AB (PUBL) : Ex-dividend day for final dividend
FA
05/07PROBIá : Annual General Meeting 2021
AQ
04/23Q1 2021 : Good growth in the first quarter
AQ
04/22PROBIá : and China National Pharmaceutical Foreign Trade Corporation have signed..
AQ
04/21PROBIá : Iron status in healthy pregnant women improved by the probiotic Probi F..
AQ
04/20PROBIá : Presentation of Probi's Q1 report 2021
AQ
04/09PROBIá : publishes Annual Report for 2020
AQ
03/29Probi and Sinopharm enter strategic partnership in China
AQ
03/25PROBI ABá : (publ) convenes the Annual General Meeting 2021 and proposes to canc..
AQ
03/10PROBIá : Strong bones are key to an active life - probiotics to play a role
AQ
More news
Financials
Sales 2021 758 M 91,1 M 91,1 M
Net income 2021 119 M 14,3 M 14,3 M
Net cash 2021 318 M 38,2 M 38,2 M
P/E ratio 2021 45,7x
Yield 2021 0,34%
Capitalization 5 424 M 650 M 652 M
EV / Sales 2021 6,74x
EV / Sales 2022 5,84x
Nbr of Employees -
Free-Float 38,6%
Chart PROBI AB (PUBL)
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 505,00 SEK
Last Close Price 476,00 SEK
Spread / Highest target 6,09%
Spread / Average Target 6,09%
Spread / Lowest Target 6,09%
EPS Revisions
Managers and Directors
NameTitle
Tom Juhani R÷nnlund Chief Executive Officer
Henrik Lundkvist Chief Financial Officer
Jean-Yves Parisot Chairman
Niklas Brandt Vice President-Information Technology
Niklas Larsson Lead Scientific Affairs
Sector and Competitors
1st jan.Capitalization (M$)
PROBI AB (PUBL)12.80%650
NESTLÉ S.A.4.39%339 438
MONDELEZ INTERNATIONAL, INC.6.67%87 612
YIHAI KERRY ARAWANA HOLDINGS CO., LTD-24.90%66 511
THE KRAFT HEINZ COMPANY26.17%53 488
DANONE8.43%45 389